Table 1.
Characteristics of AD subjects who received in vivoamyloid imaging. All subjects had frequent CERAD neuritic plaque densities. Also shown, for case with Lewy-type phosphorylated α-synuclein pathology, are the Unified Stages, (LB stages) according to published criteria (28).
| Case | Age | gender | Braak NFT |
Thal Stage |
WMR┼ | CAA┼┼ | LB present/LB Stage | Arg | TDP | IHC | SUVR | Pathology Subset |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 91 | F | VI | 5 | 1 | 2 | N | N | N | 9.4 | 1.4 | "Pure" AD |
| 2 | 88 | F | V | 5 | 2 | 3 | N | N | N | 3.7 | 1.4 | "Pure" AD |
| 3 | 84 | M | VI | 5 | 1 | 6 | N | N | N | 7.4 | 1.8 | "Pure" AD |
| 4 | 86 | F | V | 4 | 2 | 1 | N | N | N | 5.4 | 1.6 | WMR |
| 5 | 84 | M | V | 5 | 6 | 5 | N | N | N | 8.8 | 1.7 | WMR |
| 6 | 89 | F | IV | 3 | 4 | 5 | N | N | N | 1.6 | 1.4 | WMR |
| 7 | 59 | F | VI | 5 | 5 | 5 | N | N | N | 10.4 | 1.6 | WMR |
| 8 | 80 | M | V | 5 | 4 | 9 | N | N | N | 9.6 | 2.1 | WMR/CAA |
| 9 | 67 | F | V | 5 | 5 | 2 | N | N | Y | 7.2 | 1.3 | WMR/TDP |
| 10 | 88 | F | V | 5 | 8 | 4 | N | N | Y | 1.6 | 1.2 | WMR/TDP |
| 11 | 91 | F | V | 5 | 10 | 0 | N | N | Y | 6.1 | 1.8 | WMR/TDP |
| 12 | 95 | F | VI | 5 | 10 | 1 | N | N | Y | 6.1 | 1.5 | WMR/TDP |
| 13 | 78 | F | VI | 5 | 8 | 4 | N | N | Y | 8.0 | 1.5 | WMR/TDP |
| 14 | 70 | F | VI | 5 | 11 | 12 | N | N | Y | 14.2 | 1.2 | WMR/CAA/TDP |
| 15 | 69 | M | VI | 5 | 9 | 0 | Y / lll. Brainstem/Limbic | N | N | 6.0 | 1.6 | WMR/LBs |
| 16 | 79 | F | VI | 5 | 6 | 5 | Y / llb. Limbic | N | N | 8.6 | 1.4 | WMR/LBs |
| 17 | 88 | M | V | 4 | 6 | 2 | Y / llb. Limbic | N | N | 4.8 | 1.2 | WMR/LBs |
| 18 | 76 | M | VI | 5 | 8 | 12 | Y / llb. Limbic | N | N | 7.4 | 1.2 | WMR/CAA/LBs |
| 19 | 86 | F | VI | 5 | 8 | 9 | Y / llb. Limbic | N | N | 3.7 | 1.4 | WMR/CAA/LBs |
| 20 | 67 | F | VI | 5 | 5 | 4 | Y / llb. Limbic | N | N | 8.8 | 1.4 | WMR/LBs |
| 21 | 85 | F | VI | 5 | 5 | 5 | Y / l. Olfactory-Only | N | N | 7.0 | 1.2 | WMR/LBs |
| 22 | 77 | F | V | 5 | 6 | 5 | Y / llb. Limbic | N | N | 6.9 | 1.1 | WMR/LBs |
| 23 | 96 | F | V | 5 | 4 | 5 | Y / lll. Brainstem/Limbic | N | Y | 3.6 | 1.1 | WMR/LBs/TDP |
| 24 | 104 | F | IV | 3 | 4 | 3 | Y / llb. Limbic | Y | Y# | 0.5 | 1.0 | WMR/LBs/Arg/TDP |
| 25 | 92 | M | VI | 5 | 9 | 10 | Y / lll. Brainstem/Limbic | Y | Y# | 1.4 | 1.6 | WMR/CAA/LBs/Arg/TDP |
| 26 | 103 | F | V | 5 | 5 | 6 | Y / lll. Brainstem/Limbic | N | Y# | 7.4 | 1.1 | WMR/LBs/TDP |
| 27 | 85 | M | V | 5 | 3 | 5 | Y / llb. Limbic | N | Y | 9.9 | 1.3 | LBs/TDP |
| 28 | 89 | F | VI | 5 | 12 | 8 | Y/ lV. Neocortical* | N | Y | 7.8 | 1.3 | WMR/CAA/LBs/TDP |
| 29 | 82 | M | V | 4 | 5 | 4 | Y / lV. Neocortical* | N | Y | 9.6 | 1.2 | WMR/LBs/TDP |
| 30 | 77 | F | VI | 5 | 8 | 3 | Y / lV. Neocortical* | N | Y | 5.8 | 1.2 | WMR/LBs/TDP |
| 31 | 81 | M | IV | 4 | 1 | 6 | Y / lV. Neocortical* | Y | Y | 4.4 | 1.2 | LBs/Arg/TDP |
| 32 | 81 | F | VI | 5 | 12 | 12 | Y / lV. Neocortical* | Y | N | 5.3 | 1.2 | CAA/WMR/LBS/Arg |
| 33 | 72 | F | VI | 5 | 3 | 12 | Y / lV. Neocortical* | N | Y | 5.3 | 1.4 | CAA/LBs/TDP |
| 34 | 78 | M | IV | 4 | 1 | 3 | Y / llb. Limbic* | N | N | 3.6 | 1.2 | LBs |
| 35 | 63 | M | VI | 5 | 1 | 7 | Y / lV. Neocortical* | N | N | 8.9 | 1.3 | CAA/LBs |
| 36 | 91 | M | VI | 5 | 3 | 12 | N | Y | N | 6.1 | 1.9 | CAA/Arg |
| 37 | 55 | M | VI | 5 | 1 | 12 | N | N | Y | 4.7 | 1.4 | CAA/TRISOMY 21/TDP |
| 38 | 72 | M | II | 3 | 0 | 0 | N | N | Y | 4.9 | 1.1 | FTLD-TDP** |
WMR score is the sum of the parietal, temporal, frontal, and occipital lobes; each lobe was graded on a 0–3 scale (Fig 1). Those cases with a score of 2 or higher in one or more lobes were considered to have WMR in the pathology subset.
The CAA score is the sum of the following cerebral lobes: parietal, temporal, frontal, and occipital which were graded on a 0–3 scale. As nearly our entire AD series had some degree of CAA (87%), we defined CAA in the pathology subset when one or more of the cerebral lobes had a severity score of 2 or higher.
indicates pathology meeting criteria for diagnosis of dementia with Lewy bodies, #indicates pathology met criteria for diagnosis of hippocampal sclerosis.
Case 38 contained diagnostic levels and distributions of TDP-43 deposits for FTLD-TDP.
Abbreviations: Arg = argyrophilic grains disease; CAA = cerebral amyloid angiopathy; CERAD=Consortium to Establish A Registry for Alzheimer’s Disease; FTLD=frontotemporal lobar degeneration; LBs = Lewy bodies; NFT = neurofibrillary tangle; NP = neuritic plaque; TDP= TDP-43; WMR = white matter rarefaction; IHC = average percentage of cortical gray matter in the 6 cortical ROIs that was occupied by Aβ immunoreactivity; SUVr = standard uptake value ratio for the average cortical uptake of florbetapir divided by the average cerebellar uptake.